Flector® Patch and Tirosint® licensed for the US market. (24.08.2007) IBSA announces the signature of the licensing agreement with Alpharma Inc. for the marketing of Flector® Patch and Tirosint® in the US market. Flector Tissugel ® approved by the FDA (31.01.2007) Flector Tissuegel®, IBSA's patch containing 1.3% epolamine salt of diclofenac, has been approved by the FDA for the treatment of acute pain due to minor strains, sprains and contusion. The USA marketing authorisation enlightens another major achievement and a further confirmation of the expansion trend of the company. Tirosint® ready to enter the USA market (13.10.2006) Tirosint®, IBSA's L-thyroxin in soft gel capsules, has been approved by the FDA for the introduction in the USA market. Effective immediately, the US Marketing Authorisation represents a milestone achievement in IBSA's international expansion as well as a further outcome of the technological development of the company.